A t the molecular level, atherosclerosis can be defined as an assembly of hundreds of intra-and extracellular proteins that jointly alter cellular processes and produce characteristic remodeling of the local vascular environment. Ultimately, these proteomic changes produce the lesions responsible for most ischemic cardiovascular events. Unfortunately, current methods to treat and prevent cardiovascular disease focus on antecedent risk factors that are not deterministic of these changes, or on anatomic manifestations of disease that are not clinically evident until long after these proteomic changes are underway. To improve early disease detection, and to interrupt the disease process before clinical consequences occur, it is necessary to recognize the specific patterns and dynamic features of arterial protein networks that constitute the molecular signatures of healthy and atherosclerotic arterial tissues.
Previous studies have described features of the arterial proteome in murine [1] [2] [3] and cell models of atherosclerosis 4, 5 and in limited numbers of human arterial samples with and without atherosclerosis. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] The most common source of human arterial samples has been carotid endarterectomy explants from older individuals with late-stage carotid stenosis. To date, there has not been a comprehensive survey of the human arterial proteome based on a large number of human coronary and aortic samples, using contemporary liquid chromatography tandem mass spectrometry technology and subsequent identification of the proteins that signify the presence of preclinical atherosclerosis. Accordingly, we established a tissue acquisition, mass spectrometry analysis, and statistical and bioinformatic pipeline to characterize the human coronary and distal aortic arterial proteome and to identify those proteins, networks, and pathways most strongly associated with early atherosclerotic lesions. Detailed analyses of the detected proteins reveal several key features of the coronary and aortic proteome in health and disease and identify a subset of proteins that are also highly informative plasma biomarkers for the presence of coronary atherosclerosis in the clinical setting.
METHODS
The data, analytic methods, and study materials are available to other researchers for purposes of reproducing the results or replicating procedures. Specifically, the datadependent acquisition mass spectrometry (MS) and the multiple reaction monitoring (MRM) MS data along with the Skyline document have been uploaded to the Peptide Atlas. The Spectral Library used for data-independent acquisition (DIA) MS quantitation has also been uploaded to the Peptide Atlas. The data can be accessed at http://www. peptideatlas.org/PASS/PASS01066 or via FTP using the following credentials: server name: ftp.peptideatlas.org; user name: PASS01066; password: KV454u. A detailed description of all the methods can be found in the online-only Data Supplement Extended Methods.
Arterial Sample Acquisition and Pathology Grading Methods
Male and female coroner's cases of any race, ages 18 to 50 years (men) or 18 to 60 years (women) with no ante mortem clinical suspicion of coronary disease autopsied <24 hours after death were eligible for inclusion. This report includes data from the first 100 autopsies included in the study (age range: 15-55 years; 75% men; 67% white, 26% black, 7% other). The Medico-Legal Death Investigators obtain signed family consent for retrieval of anatomic specimens before the autopsy using a protocol approved by the Lousiana State Univeristy institutional review board. During the autopsy, the pathologist dissected the aorta (ligamentum arteriosum to aortic bifurcation) and left anterior descending (LAD) and removed branching arteries and adventitial or epicardial adipose tissue ( Figure I in the online-only Data Supplement). A 5-mm segment of the mid-LAD and 10-mm segment of the distal abdominal aorta (AA) were graded by the pathologist for percentage of intimal surface involvement of the following atherosclerotic changes: (1) fatty streaks; (2) fibrous plaques (FPs); (3) complicated lesions; and (4) calcified lesions, and subsequently submitted for proteomic analysis.
Clinical Perspective
What Is New?
• Proteomic analysis of human coronary arteries (n=100) and aortas (n=100) identified hundreds of proteins (n=1925) and numerous networks and pathways that are associated with early atherosclerosis.
• Atherosclerotic samples had significant reductions in mitochondrial protein abundance.
• Atherosclerotic sample proteins indicated inhibition of the insulin receptor-, peroxisome proliferator-activated receptor-α-, and peroxisome proliferator-activated receptor-γ-regulated pathways and activation of the tumor necrosis factor-regulated pathway.
• A 13-protein plasma multiplex assay based on the most promising atherosclerosis-associated proteins was strongly predictive of angiographically defined coronary artery disease in an independent clinical cohort (area under the curve=0.92; 95% confidence interval, 0.83-0.96).
What Are the Clinical Implications?
• High-resolution mass spectrometric proteomics and network analyses can produce new mechanistic insights and identify novel biomarkers for the presence of subclinical atherosclerosis.
• Advances in sample collection and high-throughput processing mean that multidimensional proteomics assays, including the proteins identified here, will be available to support precision medicine treatment and prevention in the near future.
Arterial samples were pulverized in liquid nitrogen, homogenized, and digested with trypsin (1:20) . A total of 2.0 μg of peptides per sample were analyzed using label-free quantification on a reversed-phase liquid chromatography tandem MS online with an Orbitrap Elite mass spectrometer (Thermo Scientific) coupled to an Easy-nLC 1000 system (Thermo Scientific). The analysis was operated in a data-dependent acquisition mode in the Orbitrap analyzer, followed by tandem mass spectra of the 20 most abundant peaks in the linear ion trap. One LAD and 1 AA sample (from different subjects) were excluded because of poor protein yield, leaving n=99 samples from each territory for analysis. The tandem MS data were searched against the concatenated target/decoy 20 Human Uniprot 21 database as of July 24, 2015, with only reviewed and canonical sequences used. ProteinProphet 22 was then used to infer protein identifications. Label-free quantification and subsequent median normalization of each protein was performed using weighted spectral counting.
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Statistical Analyses
Postprocessing Quality Control and Data Imputation
A total of 1925 unambiguous proteins were detected in ≥1 of the 99 LAD samples. Of these proteins, 944 had ≤50% missingness and 375 had no missingness in all 99 samples ( Figure  II in the online-only Data Supplement). Missing values for the 944 proteins with ≤50% missingness were imputed using a low rank approximation derived from nonlinear iterative partial least squares principal component analysis 24 ( Figure II in the online-only Data Supplement). In a similar manner, the AA samples revealed 1495 unambiguous proteins including 725 with ≤50% missingness.
Weighted Coexpression Network Modeling
The WGCNA package in R was used to identify distinct protein modules among the 944 proteins used for analysis. 25 The power parameter was selected such that the topological overlap connectivity (k) of the entire network approximated a scale-free topology. To assess stability of module assignments, 50 bootstrap samples of the data were created and each one interrogated using identical WCGNA parameters.
Analysis of Association With Extent of Atherosclerosis or Anatomic Location
Regression Models Both multivariate analysis of variance and generalized linear models with adjustment for age, sex, and race were used to model the distributions of the percentage of intimal surface demonstrating FP, fatty streaks, and normal (NL) intima as a function of each individual protein. In a similar manner, ordinal regression was used to examine the association between individual proteins and %FP treated as 3-level ordinal variables (FP: 0%, 1%-59%, ≥60%).
When modeling the association between proteins identified using DIA-SWATH (Sequential Window Acquisition of all Theoretical Mass Spectra) and disease or location, we also adjusted for several housekeeping proteins (Proteasome subunit beta type-2, Small nuclear ribonucleoprotein Sm D3, Receptor expressionenhancing protein 5, Ras-related protein Rab-7a) and Myosin-11 (a vascular smooth muscle cell marker protein) to account for possible differences in tissue sample volumes, cellular composition, or protein yields.
Convex Analysis of Mixtures and Protein Expression Differences in Complex Tissues Analysis
Tissue heterogeneity, where multiple tissue types are variably mixed in each individual sample, represents a major confounder when seeking to identify tissue-specific disease markers. [26] [27] [28] [29] [30] Accordingly, we used convex analysis of mixtures 31 to perform a fully unsupervised data deconvolution to define the optimal data-derived tissue types present in the heterogeneous samples and to characterize the molecular markers whose expressions are maximally enriched in each empirically defined tissue.
GO Term and Pathway Enrichment Analysis
GO Term and pathway enrichment analyses using GO Term Finder, 32 and IPA (Ingenuity Pathway Analysis, Ingenuity Systems) tools were used to characterize the evaluable proteins obtained from the arterial samples. For the analyses of selected normal and atherosclerosis-enriched samples, the significant differentially expressed proteins with |fold change| ≥1.7 and the false discovery rate corrected P value of 0.05 were analyzed with IPA for pathways, upstream regulators, and associated diseases and biological functions. The fold change cut point of ≥1.7 was chosen to yield ≈100 proteins for further analysis. Sensitivity analyses were also performed using proteins selected purely on the basis of q-value ≤0.01 for FP versus NL.
Differential Dependent Network Analyses
Significant rewiring of biological networks provides a unique perspective on phenotypic transitions that can occur in biological systems. [33] [34] [35] We used knowledge-fused differential dependency networks [36] [37] [38] to systematically characterize significant network rewiring in the arterial proteome between normal and FP samples. We then used permutation-based significance tests to estimate P values of detected differential dependence edges.
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MRM Assay Design
The 38 proteins identified by data-dependent acquisition MS analysis to be the most highly associated with FPs were selected as candidate circulating biomarker proteins. The top 3 to 4 performing peptides from each protein were included for downstream MRM-method building. Five proteins (DRB1, LCP1, RNASE1, MTHFD1, and CALU) were excluded at this step for the absence of any detectable peptides in a reference plasma sample. Unscheduled MRM methods were developed against 323 fragments from 86 peptides for the remaining 33 putative FP marker proteins. The MRM data for plasma samples from the case and control coronary artery disease validation cohort were acquired on a SCIEX QTRAP6500 using MRM scanning in positive mode (Framingham, MA).
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Manual filtering eliminated an additional 8 proteins from further analysis because of low or undetectable signal-to-noise ratios (CATB, TSP1, NNMT, S100A9, ITIH2, POSTN, CORO1A, and HTRA). The final 25 candidate proteins were processed to generate protein-level abundance data from the endogenous peptides.
Prediction of Coronary Artery Disease From the Candidate Plasma FP Biomarkers
An adaptive elastic net model (α=0.9) 39-41 optimized by leave-one-out validation was used to select among the 25 candidate biomarkers for prediction of case status. Biascorrected bootstrap sampling (n=10 000) was used to evaluate overall performance of the optimized model based on median (95% confidence interval) area under the curve from the bootstrap samples.
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RESULTS
Global Analysis of Coronary and Abdominal Aortic Proteomes Identifies Novel Arterial Proteins and Scale-Free Network Topologies
Based on stringent quality control and calling criteria, a total of 1925 unambiguous protein groups (hereinafter referred to as proteins) were identified in ≥1 LAD coronary artery or distal AA samples, including 974 proteins present in ≥50% of the LAD or AA samples (Table I in the online-only Data Supplement). The 974 proteins represent a wide range of biological processes, molecular functions, cellular components, and canonical pathways 43 (Figures III to V in the online-only Data Supplement and Tables II to IX in the online-only Data Supplement). Of the 1925 proteins, 43 have not been previously described in 13 prior studies that directly analyzed protein content of human arterial tissues (Table I in the online-only Data Supplement). All but 8 of these proteins were nevertheless predicted based on RNASeq analysis of human coronary or aortic samples from the GTEX Consortium. 44 The 944 proteins unique to the LAD exhibited a scalefree network topology typically seen in complex adaptive networks of molecular or cellular constituents from a variety of living organisms [45] [46] [47] ( Figure 1 ). Furthermore, these proteins included several distinct and reproducible coexpression modules that roughly correlated with specific cellular functions and locations such as mitochondrial proteins involved with cellular respiration (red module), nuclear proteins involved with chromatin assembly and organization (turquoise module), and extra cellular matrix proteins (brown module). A similar scalefree topology and functional modular structure was also evident in the protein data from the AA ( Figure VI in the online-only Data Supplement). A scale-free topology suggests that the arterial proteome may arise from a complex adaptive system with properties such as selforganized criticality, emergence, and resilience. 46, 48, 49 Complex adaptive systems are uniquely well suited for description using graph theory and network or nonlinear dynamic modeling to reveal functional insights that may be less evident from more conventional linear conceptual models and methods 33, 50, 51 (see below). The number and diversity of proteins detected, and the fact that they exhibit a scale-free topology, lends internal validity to our protein extraction and measurement approach and suggests that features of a complex adaptive system that are evident in gene transcript data remain after translation and protein catabolism.
Comparison of Normal Coronary and Aortic Proteomes Reveal Significant Differences in Mitochondrial Protein Mass
Several hundred proteins were detected in the LAD but not in the AA samples ( Figure VII in the online-only Data Supplement). This pattern was observed when limiting the analysis to completely normal samples (n=30 in each territory) or when limiting the proteins to those present in ≥50% of the LAD and AA samples. GO Term analysis of the proteins exclusively detected in the LAD indicated significant enrichment of mitochondrial proteins (P value range, 1.7×10 -6 to 1.8×10 -28 ). To confirm this apparent differential abundance of mitochondrial proteins between LAD and AA samples, we performed a more sensitive DIA-MS (also known as SWATH) analysis of entirely normal samples (n=30 in each anatomic location), focusing on 114 quantified mitochondrial proteins involved with fatty acid metabolism, oxidative phosphorylation, tricarboxylic acid cycle, and mitochondrial biogenesis. To account for possible site and sample differences in cellular material or protein extraction yields, the quantitative results were adjusted for several smooth muscle cell-specific housekeeping proteins and age and sex of the autopsied cases. Overall, mitochondrial proteins were 1.98-fold more abundant in the LAD than in the AA (P<0.001) including a 2.25-fold increase in oxidative phosphorylation proteins (P<0.001) and an isolated >10-fold excess of inorganic pyrophosphatase (P<0.001; Figure 2) . A similar comparison of soluble extracellular matrix (ECM) proteins revealed only a small, albeit statistically significant (P=0.01) 6% excess in soluble ECM proteins in the AA samples in comparison with the LAD (Figure VIII in the online-only Data Supplement). A notable exception was tenascin which had a >10-fold excess in AA samples in comparison with LAD (P<0.0001).
These data suggest fundamental differences in mitochondrial mass and potential aerobic capacity between LAD and AA tissues, possibly reflecting the differing energy requirements of these 2 arterial tissue types. This heterogeneity in the proteomic profile of 2 arterial tis-sues emphasize the need for arterial anatomic specificity when characterizing the proteomics and functional biology of arterial tissues, especially if considering mechanisms or interventions that involve metabolic pathways (see below). Second, convex analysis of mixtures 52 was used to deconvolve the global protein profiles from individual samples into unsupervised data-derived tissue phenotypes and to identify marker proteins associated with each phenotype (LAD, Figure 3 ; AA, Figures X and XI in the online-only Data Supplement). This approach has the advantage of generating information about tissue phenotype from global protein profiles independent of the pathologist's visual inspection of the arterial samples.
Atherosclerotic Tissues in
To take full advantage of both phenotyping strategies, we used principal component analysis and hierarchical clustering of the pathologist-and convex analysis of mixtures-derived phenotype data to produce a pathoproteomic classification for each LAD sample (Figure 4) . Clusters at the extremes of the first principle component identified samples highly enriched with FP or NL tissue (FP: n=15; NL: n=30) with little or no confounding from fatty streaks from either a gross pathology or global proteomic perspective.
Comparing these FP-and NL-enriched LAD samples identified 89 individual proteins with ≥ (+/-)1.7-fold difference and a t test q-value of ≤0.05 for FP versus NL (Tables XII and XIII in the online-only Data Supplement). Bioinformatic functional analysis of these atherosclerosis-associated proteins revealed a pattern consistent with activation of the tumor necrosis factor-α (TNF-α) pathway (P=2.64E-07), but also inhibition of insulin receptor, peroxisome proliferator-activated receptor-α (PPAR-α), and peroxisome proliferator-activated receptor-γ (PPAR-γ) pathways (P=4.22E-10, 2.42E-13, 8.56E-16, respectively) (Figure 4 , Tables XIV and XV in the online-only Data Supplement). A similar analysis of the atherosclerosis proteins in the AA samples (FP: n= 9, NL: n=18) also produced a pattern consistent with TNF activation (P=1.92E-05) similar to the LAD (Tables XVI and XVII in the online-only Data Supplement) and highlighted a core group of n=19 early atherosclerosis-associated proteins that were shared across both anatomic territories (Table XVIII in the online-only Data Supplement). However, in the AA sample proteomes, there was no compelling evidence of inhibition of the insulin receptor, PPAR-α, or PPAR-γ pathways (Table XIV in the onlineonly Data Supplement). In sensitivity analyses using only a t test q-value of ≤0.01 for FP versus NL samples, qualitatively similar results concerning upstream regulators and regulated pathways were observed (Table XIX in the online-only Data Supplement). The apparent inhibition of the insulin receptor, PPAR-α, or PPAR-γ pathways in atherosclerotic samples from the LAD and AA suggests that there are fundamental metabolic derangements already present in early atherosclerosis. 19) , and inhibition of PPAR-α (P=3.55E-10, z score=-3.06), PPAR-γ (P=2.87E-10, z score=-3.02), and the insulin receptor (P=1.41E-12, z score=-2.16). PPAR-α, PPAR-γ, and the insulin receptor pathways are themselves inhibited by TNF activation. When using >1.5-fold change criteria, several additional regulatory networks were also identified (eg, TGFB1, TP53, SP1, MYC). E, Predicted disease processes and their affiliated proteins significantly overrepresented by the up-and downregulated proteins in fibrous plaques. The data are consistent with major alterations in cell-cell adhesion/ interaction (P=3.64E-03), lipid uptake (P=1.67E-03), glucose homeostasis (P=2.83E-06), and blood pressure regulation (P=3.68E-03). CAM indicates convex analysis of mixtures; FP, fibrous plaques; FS, fatty streaks; PPAR-α, PPARA, peroxisome proliferator-activated receptor-α; PPAR-γ, PPARG, peroxisome proliferator-activated receptor-γ; and TNF, tumor necrosis factor. An important feature of complex adaptive systems is the potential for network topologies to change under different conditions. Accordingly, we used differential dependent network analysis of the FP-associated proteins identified above to select proteins pivotal in the rewiring of the network structure between NL and FP in the LAD samples ( Figure 5 ). Analysis of n=26 rewiring hub proteins revealed significant enrichment of tricarboxylic acid proteins (P=4.8×10 -6 ). Subsequent analysis of individual tricarboxylic acid proteins documented an average 60% reduction in tricarboxylic acid proteins in FP-enriched samples versus NL.
DIA-MS analysis of the same broad-based panel of n=114 mitochondrial proteins used previously was performed comparing FP versus NL samples from the LAD (Figure 6) . The results document a consistent reduc- 
ORIGINAL RESEARCH ARTICLE
tion of a wide range of mitochondrial proteins in the FP samples in comparison with NL samples after adjustment for vascular smooth muscle-specific housekeeping proteins, age, and sex. In contrast, a similar analysis of the same proteins in AA samples revealed a much less consistent and nonstatistically significant pattern of mitochondrial protein suppression. To determine if this was a mitochondrial-specific phenomenon, we also performed targeted DIA-MS analysis of a targeted panel of soluble ECM proteins (n=77) and 
Clinical Validation of the Plasma Multiplex Atherosclerosis Biomarker Panel
To establish that FP proteins discovered by using human arterial samples could serve as informative plasma biomarkers of coronary atherosclerosis, we developed a highly reproducible MRM assay for a subset of 25 of these proteins that were measurable in plasma ( Figure  XIII in the online-only Data Supplement). Subsequently, we compared fasting levels of these proteins in 45 women with angiographically verified coronary atherosclerosis (cases) and 41 similar-aged women who were free of signs, symptoms, or risk factors for coronary disease (controls) (see Methods). An elastic net model identified 13 proteins that jointly contributed to prediction of case status while also avoiding overfitting ( Figure 7A and 7B). The bias corrected median (95% confidence interval) area under the curve for this model based on 10 000 bootstrap samples was 0.92 (0.83-0.96) and the median misclassification rate was 0.13. Among individual proteins with the largest effect sizes, vitronectin, transforming growth factor-β-induced protein, complement factor 7, and apo B were positively associated with the presence of coronary atherosclerosis, and tripeptidyl-peptidase 1, ITI heavy chain H1, and leukotriene A-4 hydrolase were negatively associated.
DISCUSSION
The results here provide a comprehensive survey of human coronary and aortic proteins and identify individual proteins, protein networks, and regulatory pathways that differ between arterial beds or that are indicative of early atherosclerosis. These data can be distinguished from prior work because of the inclusion of human coronary arteries that are responsible for the majority of acute ischemic vascular disease morbidity and mortality, the number and diversity of proteins identified, and the fact that these proteins were obtained from a large number of samples where the effects of local tissue context and natural biological variation are manifest. Several analytic methods were used to illuminate complex networks involving many proteins that jointly signify arterial health and disease. It is important to note that these data also show that proteins discovered using comprehensive tissue proteomics can be used to develop highly informative multiplex plasma biomarker assays with direct clinical utility. The publicly accessible data generated by this work, and the analytic methods depicted here, represent additional resources that may lead to a wide range of future translational research concerning human arterial protein biology. There are several notable findings among the many results reported here. First, the human arterial proteome exhibits features consistent with a complex adaptive network, reiterating the concept that complex adaptive networks are an overarching organizational feature common to many biological systems. 53 Transcriptional profiles are well known to exhibit features of a complex adaptive system. 54 To our knowledge, this has not been demonstrated at the protein level in human arterial tissue in such a large number of samples as described here, although others have described features of a complex adaptive system in proteomic analysis of human ovarian tumors. 55 The fact that our data do indeed resemble a complex adaptive network lends internal validity to our rendering of the arterial proteome. Looking at the arterial proteome through the lens of complexity theory including concepts such as scale invariance (as documented here), self-organized criticality, emergence, and resiliency 46, 48, 49 may produce insights that have escaped more narrowly focused investigations of a smaller number of proteins or a more linear and deterministic framework. The differential dependent networks presented here emphasize this point by defining dynamic features of complex protein networks that signify normal versus atherosclerotic arteries and by using key elements of these dynamic networks to discover important aspects of the proteome in atherosclerosis that were not easily evident by other means.
Second, the data reveal significant anatomic variation in the abundance of mitochondrial proteins in normal arterial samples, suggesting that coronary arteries likely have considerably greater aerobic capacity than the distal aorta. This fits our understanding of the different embryology 28 and normal physiological roles of these distinct regions of the arterial system with the coronary arteries having greater energy requirements associated with the regulation of coronary blood flow in comparison with the distal aorta that serves primarily as a passive conduit for blood delivery to the lower extremities. To our knowledge, this substantial variation in mitochondrial protein mass between coronary and aortic tissues in humans has not been previously documented.
Third, the data indicate profound anatomic differences in key metabolic regulatory pathways and mitochondrial dynamics in the setting of atherosclerosis. Specifically, the data reveal a broad-based reduction of
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mitochondrial protein mass and a proteomic pattern consistent with inhibition of PPAR-α, PPAR-γ, and insulin receptor-regulated pathways in atherosclerotic coronary arteries, but not in similarly diseased distal abdominal aortic samples. These data provide critical anatomic specificity to the growing body of evidence that mitochondrial dysfunction and altered mitochondrial dynamics are also central features of atherosclerosis, 15 ,56,57 and may provide a mechanistic framework to explain the anatomic dimorphism between coronary and peripheral arterial disease with respect to conventional and genetic risk factors for atherosclerosis. 58, 59 It remains to be determined whether the reduction in mitochondrial protein mass in coronary atherosclerosis is a consequence of oxidative, or Ca
2+
-mediated mitochondrial damage and mitophagy, impaired mitochondrial biogenesis, or both. It is interesting to note that the concurrent increases in the lysosomal cathepsins in Figure 7 . Clinical validation of fibrous plaque proteins. A, Solution path for the elastic net model (α=0.9) with parameter estimates as a function of increasing number of variables entered into the model as reflected by the sum of the Scaled Parameter Estimates. The generally monotonically increasing solution paths suggest relative stability and no major interactions among the proteins included in the model. B, The -LogLikelihood derived from the leave-one-out validation samples as a function of increasing number of variables entered into the model. The negative inflection point indicates the optimal feature selection after which adding additional variables lead to worsening (increasing) -LogLikelihoods because of overfitting of the data. C, The ROC curve for the optimal model predicting the presence of angiographically proven coronary disease. Bootstrap estimates of the AUC and its 95% CI based on 10 000 samples were 0.93 and 0.85 to 0.97, respectively. D, Parameter estimates for proteins included in the plasma protein biomarker panel. Six proteins (indicated in bold) had the strongest evidence for contributing to model performance. However, elastic net models permit the inclusion of additional variables that may be correlated with other terms in the model. These proteins may not individually contribute greatly to the overall prediction performance, but nevertheless participate in underlying mechanistic pathways worthy of further consideration. AUC indicates area under the curve; CI, confidence interval; ROC, receiving operating characteristic; and TGF-B, transforming growth factor beta. the atherosclerotic samples may signify enhanced lysosomal biogenesis useful for targeted degradation of damaged mitochondria. 56 The data also reassuringly highlight numerous individual proteins and a global proteomic pattern of TNF-α activation in the FP samples consistent with several decades of research documenting the role of inflammation in the pathogenesis of atherosclerosis. 60 However, even the more familiar indicators of TNF-α activation and inflammation exhibited substantial anatomic variation from LAD to distal aorta in our data.
Recognizing the anatomic heterogeneity with respect to mitochondrial and metabolic enzyme profiles has important implications for research on arterial health and disease. Many of the pathogenic mechanisms and targeted therapies for atherosclerosis are directly related to fatty acid metabolism or aerobic energy biosynthesis and redox homeostasis. 61 Unfortunately, a great deal of our understanding of arterial biology has been generated without regard to anatomic distribution. For instance, many animal models of atherosclerosis rely on aortic, femoral, or carotid manifestations of disease with the assumption that findings are generalizable to human coronary arteries. Likewise, the overwhelming majority of human arterial proteomic data have been generated from carotid arteries, typically severely diseased endarterectomy specimens. The current data suggest that a complete understanding of the pathogenesis and prevention of human arterial atherosclerosis may require more anatomically specific methods of interrogation.
Finally, the data demonstrate the translational potential of proteomics from complex human tissues to identify clinically informative plasma biomarkers. Although significant portions of the arterial proteome reside in compartments inaccessible to the plasma blood pool, there are many others that are secreted or released into the circulation, and the plasma concentrations for some of these, such as vitronectin, are uniquely informative about the presence of early atherosclerosis. The prominent contribution of vitronectin as an atherosclerosis biomarker is plausible based on accumulating evidence that this polyfunctional matricellular protein plays a critical role in organizing the earliest response to tissue injury. 62 Similarly compelling arguments can be made in support of many of the other atherosclerosis-associated proteins (eg, CD5 antigen-like, complement factor I, and complement component C7). However, based on the data presented here, early atherosclerosis is likely best revealed through changes in a complex array of many proteins rather than any single sentinel protein. It is fortunate that recent advances in mass spectrometry technology now permit sophisticated multiplex assays to measure many more proteins with very small plasma volumes, making multidimensional proteomics assays such as the one described here a clinical possibility in the near future.
Several limitations in the current work should be considered. First, although a comprehensive analysis of 200 human arterial specimens is a considerable technical accomplishment, and despite the fact that we used stringent statistical methods and other information theoretical considerations to minimize false positives (generally to ≤5%), there remains the possibility of residual confounding or limited statistical power that could obscure both positive and negative associations. The fact that many of the sentinel findings generated by the initial data-dependent MS approach were subsequently confirmed and strengthened by a separate data-independent acquisition MS method (which uses different peptides for protein identification) provides further support for the validity of the findings. Second, highly cross-linked ECM proteins can be relatively refractory to extraction without specialized solubilization strategies. 63 Accordingly, there may be differences in tissue ECM composition by anatomic location or disease status that are not evident based on the soluble fraction examined here. This limitation notwithstanding, we were able to achieve excellent ECM coverage including collagens, fibronectin, elastins, lamins including heparin sulfate and chondroitin sulfate proteoglycans (see Table I in the online-only Data Supplement). We attribute this to the fact that we used both data-dependent acquisition and DIA acquisitions to maximize peptide detection and protein identification. Third, the fact that the samples were all collected postmortem raises questions about possible effects of death on the stability of individual proteins or specific cellular functional processes. If such effects are differentially manifest in normal versus atherosclerotic tissues, this could give the appearance of differences by disease status that are not present during life. It is reassuring that many of the individual proteins identified here overlap with findings from animal models of atherosclerosis and in vitro studies where the effects of postmortem hypoxia and cessation of cellular metabolic activity are more easily minimized. Fourth, the observed differences in the proteome between normal and diseased samples represent a unique, albeit macroscopic view of the proteomic architecture of human coronary and distal aortic atherosclerosis. More work is required to clarify the functional role of the specific proteins, protein networks and pathways identified here, and to establish if there is therapeutic value in manipulating them. Nevertheless, the data already reveal the potential clinical utility of a diverse array of plasma proteins as atherosclerosis biomarkers even as their mechanistic underpinning continue to be explored.
In summary, these data represent the most comprehensive description of the human coronary and aortic proteome to date and reveal numerous proteins, networks, and pathways that are strongly indicative of early atherosclerosis. They also indicate fundamental differences in mitochondrial dynamics
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between the coronary artery and the distal aorta in both normal and atherosclerotic conditions. The data highlight the value of new methods to extricate tissue phenotypes from heterogeneous tissue samples and depict dynamic features of protein networks that vary as a function of disease state and anatomic location. The results illustrate the potential utility of using tissue proteomics to identify plasma biomarker and provide evidence of the clinical utility or a multiplex biomarker panel to indicate the presence of coronary atherosclerosis. Altogether these data and methods establish a new foundation for research to better understand the human arterial proteomic architecture in health and disease.
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